Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 , an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
European Commission Approves KEYTRUDA® Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia
FDA Approves BRAVECTO® QUANTUM from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
FDA Approves NUMELVI for Dogs from Merck Animal Health - The First and Only Second-Generation Janus Kinase Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir , an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
Metalsource Mining Intersects 48.04 g/t AuEq over 12.62m, Including 210.72 g/t AuEq over 2.74m, Extends Mineralization down Dip 195m, Continues to Expand Gold, Silver and Base Metal Mineralization
EnerCom Opens Registration for the 31st Annual Energy Investment Conference August 17-19, 2026 in Denver, Colorado
QIMC Details Multiple Shallow Hydrogen-Bearing Zones in Drill Hole 26-02 and Advances Integrated Interpretation of Holes 1 and 2; Drill Hole 2 to be Extended to 700 Metres; Drill Mobilized for Hole 3
